Compare IDEXX Laboratories, Inc. (IDXX) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Quantumscape Corp — how do they compare? IDEXX Laboratories, Inc. trades at $570.99 (market cap $46.22B), while Quantumscape Corp trades at $6.34 (market cap $3.90B). The key difference: IDEXX Laboratories, Inc. is far larger — about 11.9× Quantumscape Corp's market cap. Which is the better fit depends on your goals.
| IDXX | QS | |
|---|---|---|
Market Cap | $46.22B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $18.44 |
52-Week Low | $526.44 | $4.89 |
Enterprise Value | $47.12B | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
QuantumScape trades at $6.34, up 2.42% today, with a bullish technical signal but mixed sentiment. The company remains pre-revenue, reporting a net loss of $435.05M in 2025, with negative ROE and ROA. Recent earnings showed beats on EPS estimates, but commercialization timelines have been delayed to 2029, fueling investor skepticism.
The outlook hinges on successful battery technology commercialization by 2029, presenting high-risk, high-reward potential. Key risks include execution delays, intense competition, and reliance on financing. Analyst consensus is cautious, with no buy ratings, reflecting significant uncertainty around the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
